CClinicalTrials.gg
RecruitingNCT07172113Updated Sep 15, 2025

Utilizing Embodied Artificial Intelligence (AI) for the Development of Digital Cognitive Behavioral Therapy (CBT) for Depression in Virtual Reality (VR)

An interventional study of CBT + VR in Depression Scale Score, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Depression is a prevalent mental disorder characterized by pervasive low mood, diminished interest or pleasure, and a range of cognitive and physical symptoms. According to the World Health Organization (WHO), depression is a leading cause of disability worldwide, affecting approximately 280 million individuals of all ages. In spite of the widespread occurrence and negative consequences linked to depression, fewer than 30% of individuals with common mental disorders sought assistance from mental health services in the previous year due to reasons such as, high-cost and stigma.

Cognitive behavioral therapy (CBT) is the gold-standard and evidence-based intervention for various mental health disorders, including depression, anxiety, and its effectiveness has been widely proven. With the recent advancement in AI and other relevant technologies, the use of digital CBT has become possible. Indeed, a recent systematic review demonstrated a comparable effectiveness of traditional CBT and digital CBT, after controlling the moderators (e.g., intervention duration, and adherence). While digital CBT has achieved impressive performance, the majority of them utilized web-based or app-based platforms. Therefore, one of the disadvantages of such digital CBT is the lack of interaction between (digital) therapists and clients. Additionally, lower adherence to digital interventions was observed, indicating the need for briefer sessions, such as single-session integrated CBT (SSI-CBT), for digital interventions. SSI-CBT involves a collaborative effort between the therapist and the client, aimed at assisting the client in accomplishing their desired outcome within a single session. It is understood that additional support is accessible if required. A recent study using SSI-CBT demonstrated promising results of its effectiveness in reducing depression and anxiety, which can last for two months. To further generalize the application of digital interventions, a more interactive virtual therapist utilizing a brief CBT-based intervention approach is desired.

This study will evaluate the effectiveness of virtual CBT therapist for reducing depression symptoms, compared to a waitlist control group. Based on previous research, it is expected that a virtual CBT therapist can significantly reduce the depression symptoms at both post-intervention and one-month follow-up.

02

Conditions studied

  • Depression Scale Score
03

In context

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Chinese young adult aged 18-40 years
  2. Native Cantonese speaker
  3. Presence of depressive symptoms, as indicated by a score of 10 or higher on the depression sub-scale of the Depression Anxiety Stress Scale 21 (DASS-21).
  4. Able and willing to comply with the requirements of the study protocol

Exclusion criteria

Exclusion Criteria:

  1. A current or history of any psychiatric disorder(s) other than depressive disorder and anxiety disorder, such as bipolar disorder, psychotic disorders, and substance use disorder
  2. A current or history of any voice, speech, and language disorders
  3. A current or history of non-suicidal self-injury or suicidality
  4. Incompetent in giving informed consent for participation in the study
  5. A current or history of significant motion sickness, active nausea, and vomiting or epilepsy.
  6. A current or history of color vision deficiency
  7. Subject who is preparing for pregnancy or pregnant
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intervention group

    The VR group will receive one session CBT via a VR headset. The session will last for around 45 mins. During the intervention, the participants can freely talk to the virtual therapist using natural language input.

    Device: CBT + VR

  • No intervention
    Control group

    This group will serve as a waitlist control group. They will not receive the intervention until the study end.

Interventions

  • DeviceCBT + VR

    This CBT intervention is conducted in VR using Embodied AI technology. A virtual therapist will present in a virtual therapy room. Participants can freely talk to and interactive with the virtual therapist.

06

What researchers measure

Primary outcomes

  1. The Depression Subscale of the Depression, Anxiety and Stress Scale - 21 Items (DASS-21)

    The depression sub-scale of DASS-21 comprises seven items that are assessed on a 4-point Likert scale, ranging from 0 (Did not apply to me at all) to 3 (Applied to me very much). The international cut-off values are as follows (as multiplication of sum by 2): 0-9 for normal, 10- 13 for mild, 14- 20 for moderate, 21- 27 for severe and 28 or above for extremely severe.

    Time frame: Baseline and 1 month

Secondary outcomes

  1. The Satisfaction With Life Scale (SWLS)

    The SWLS, containing 5 items, will be used to assess participants' life satisfaction. Items are scored based on a 7-point scale from strongly disagree (1) to strongly agree (7). A higher mean score indicates a greater satisfaction with life.

    Time frame: Baseline and 1 month

  2. The revised General Help-Seeking Questionnaire (GHSQ)

    The revised GHSQ contained first 10 questions from the original GHSQ, asking people's intention to seek help from various sources, and further incorporated 9 follow-up questions, asking people's attitude to seek help from various sources. All items are scored based on a 7-point scale, ranging from extremely unlikely (1) to extremely likely (7) for the first 10 intention-related items, and from extremely unhelpful (1) to extremely helpful (7) for the last 9 attitude-related items. A higher mean score indicates a greater intention and attitude to seek help.

    Time frame: Baseline and 1 month

07

Study locations

1 of 1 sites recruiting
  • The Chinese University of Hong Kong
    Hong Kong, Hong Kong
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07172113
Lead sponsor
Chinese University of Hong Kong
Responsible party
Tim M. H. Li (Prof., Chinese University of Hong Kong) — Principal investigator
First posted
Sep 15, 2025
Start date
Mar 7, 2025
Primary completion
Sep 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Sep 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion